1-(6-((2,5-Dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-2-(3-(1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)prop-1-en-1-yl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate
- Catalog No. :
- ACJWLY119
- CAS No. :
- 146397-20-8
- Molecular Formula :
- C43H50N4O14S2
- Molecular Weight :
- 911.02
IUPAC Name:1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-2-((E)-3-((E)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)prop-1-en-1-yl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$954.00Login to see priceInquiryInquiry
250mg97%$1553.00Login to see priceInquiryInquiry
Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.
0 Reviews:View Reviews
Product Information
| Product Name | 1-(6-((2,5-Dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-2-(3-(1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)prop-1-en-1-yl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate |
|---|---|
| IUPAC Name | 1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-2-((E)-3-((E)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-sulfoindolin-2-ylidene)prop-1-en-1-yl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate |
| MDL No. | MFCD28978247 |
| Molecular Formula | C43H50N4O14S2 |
| Molecular Weight | 911.02 |
| SMILES | CC1(C)C(/C=C/C=C2/N(CCCCCC(=O)ON3C(=O)CCC3=O)C3=CC=C(S(=O)(=O)O)C=C3C2(C)C)=[N+](CCCCCC(=O)ON2C(=O)CCC2=O)C2=C1C=C(S(=O)(=O)[O-])C=C2 |
| InChI Key | OHOQEZWSNFNUSY-UHFFFAOYSA-N |
| Synonym | Cy3;2-((1E,3E)-3-(1-(5-Carboxypentyl)-3,3-diMethylindolin-2-ylidene)prop-1-enyl)-1-ethyl-3,3-diMethyl-3H-indoliuM chloride;Cy3 DiSE(DiSO3);Cy 3 acid;Cy3-bifunctional dye zwitterion;Sulfo-Cyanine3 DiNHS ester;Cy 3 Non-Sulfonated;Cy3 DiSE(DiSO3) sulfo Cy3 diSE.TEA |
| CAS No. | 146397-20-8 |
Safety Data
- Pictogram
- Signal Word
- Warning
- Hazard Statement(s)
- H302-H315-H319-H335
- Precautionary Statement(s)
- P261-P305+P351+P338

